Sunday, March 29, 2026 – NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and...
Sunday, March 29, 2026 – (MedPage Today) -- The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a...
Sunday, March 29, 2026 – A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It's a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?
Sunday, March 29, 2026 – (MedPage Today) -- GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients...
Sunday, March 29, 2026 – (MedPage Today) -- The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the...
Sunday, March 29, 2026 – (MedPage Today) -- Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered...
Sunday, March 29, 2026 – Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I study will evaluate UX-GIP001 in patients with drug-resistant epilepsy.
Sunday, March 29, 2026 – (MedPage Today) -- Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn't held prior to upper endoscopy unless they were on a clear liquid diet the day before, the OCULUS randomized trial...
Sunday, March 29, 2026 – (MedPage Today) -- For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation...
Sunday, March 29, 2026 – The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.